



Biotech Daily

Thursday October 1, 2026

Daily news on ASX-listed biotechnology companies

- * ASX, BIOTECH DOWN: OPTISCAN UP 18.5%; IMPEDIMED DOWN 20%
- * SKOPOS RAISES \$12m FOR PROSTATE CANCER RADIATION
- * SEPTEMBER BDI-40 UP 1%, ASX200 DOWN 1%, BIG CAPS UP 2%, NBI FLAT
- * LTR: SPONTAN ERECTILE DYSFUNCTION SPRAY 'FASTER THAN TABLETS'
- * MONASH UNI TRIALS BACTERIAL VAGINOSIS CURE
- * ADELAIDE UNI DEVELOPS HONEYBEE SILK WOUND DRESSING
- * SYNTARA: '8 PATIENTS DISCONTINUE SNT-6302 DUE TO SKIN REACTIONS'
- * CLINUVEL: 3 MORE VITILIGO PATIENTS RESPOND TO SCENESSE
- * AROVELLA STARTS PHASE I ALA-101 BLOOD CANCER SCREENING
- * CHIMERIC LATE REPORTS, CREDITOR TALKS, SUSPENDED
- * NYRADA GRANTED US XOLATRYP PATENT
- * NEUROSCIENTIFIC APPOINTS PHASE II STEMSMART CROHN'S DISEASE CRO
- * ADALTA TO OPEN CHINA OFFICE
- * CORRECTION: PAINCHEK
- * OPTISCAN FILES INFORM SYSTEM 510(k) TO FDA
- * ADHERIS BOARD, MANAGEMENT TAKE 4.2%
- * ARGENT TAKES \$720k C/M, WVP LOANS
- * DAVID PARADICE, PARADICE INVESTMENT TAKE 5% OF ARTRYA
- * MERCER TAKES 8% OF MICROBA
- * DR RUSSELL BASSER TO REPLACE STARPHARMA CHAIR ROB THOMAS
- * CHIMERIC: PHILLIP HAINS INTERIM CHAIR, CEO TO M-D, 2 DIRECTORS GO
- * NEXSEN APPOINTS PROF SHEKHAR KUMTA EXECUTIVE ON \$275k PA
- * BTC APPOINTS DR IAN KADISH DIRECTOR
- * DR CHRIS BREMER STARTS AS NEURIZON CEO

MARKET REPORT

The Australian stock market fell 1.99 percent on Thursday October 1, 2026, with the ASX200 down 174.9 points to 8,614.4 points. Six of the Biotech Daily Top 40 companies were up, 25 fell, seven traded unchanged and two were untraded. All four Big Caps fell.

Optiscan was the best (see below), up 2.5 cents or 18.5 percent to 16 cents, with 724,994 shares traded. Micro-X climbed 10.5 percent; Botanix was up 5.6 percent; Saluda rose 3.6 percent; with 4D Medical and Dimerix up more than two percent.

Yesterday's best, Impedimed, led the falls, down 0.1 cents or 20 percent to 0.4 cents, with 7.3 million shares traded. Starpharma lost 8.6 percent; Imugene was down 7.1 percent; Aroa and Cochlear shed more than six percent; EBR was down 5.4 percent; Alcidion, Clinuvel, Curvebeam and Syntara fell more than four percent; Artrya and CSL were down more than three percent; Actinogen, Avita, Immuteq, Nanosonics, Polynovo and Resonance shed more than two percent; Cyclopharm, Emvision, Imricor, Mesoblast, Neuren, Nova Eye, Prescient, Pro Medicus, Racura and Resmed were down more than one percent; with Telix down by 0.7 percent.

SKOPOS BIO, PETER MACCALLUM CANCER CENTRE

Peter MacCallum Cancer Centre spinout Skopos Bio says it has raised \$12 million in a seed round to develop radiation for prostate cancer.

Skopos said its three founders were Peter MacCallum Cancer Centre clinical and translational scientists, Prof Michael Hofman, Prof Mohammad Haskali and Prof Luc Furic. The company said the seed round was led by co-lead Dr Andrew 'Twiggy' Forrest's Tenmile, with Tin Alley Ventures and Yosemite Venture Fund founded by Reed Jobs. Skopos said the funds raised would be used to advance its lead prostate cancer program, based on research developed at Peter MacCallum Cancer Centre "through human proof-of-concept and pipeline development".

The company said that it was "designing radio-active molecules engineered to seek out and bind to cancer cells, delivering radiation directly to tumors while largely sparing healthy tissue".

Skopos said the approach had "the potential to reach a wide range of cancers that are difficult to treat with conventional radio-therapy or existing drugs".

The company said that laboratory results were "promising, with the company's lead program now moving towards first-in-human clinical trials".

Skopos said that it was chaired by Jeevan Virk, who had 20 years' experience in radio-pharmaceuticals, and had been employed by Novartis and had worked on Lutathera and Pluvicto, two approved radiation-based cancer medicines.

The company said that Prof Hofman was the director of the Peter MacCallum Cancer Centre's 'prostate theranostics and imaging centre'; Prof Haskali was the Centre's inaugural chief radio-pharmaceutical scientist and Prof Furic was a "cancer biologist and ... [the Centre's] head of translational prostate cancer research".

Prof Haskali said that "the idea of targeting cancer with radiation isn't new".

"What's new is the chemistry that makes it possible to hit the right target, safely, in a patient," Prof Haskali said.

"We have spent years developing that chemistry and it's the foundation [on which] this entire program is built," Prof Haskali said.

Skopos is a private company.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

September was a strange month for the Biotech Daily Top 40 Index (BDI-40).

The BDI-40 was up 0.8 percent to a collective market capitalization of \$20,813 million, but 22 companies were down for the month, of which 13 fell more than 10 percent; 15 companies were up, with 10 up by more than 10 percent; and three were unchanged.

The \$505 million or 24.6 percent improvement in 4D Medical's fortunes – to \$2,557 million - explains the quandary.

The benchmark ASX200 fell 3.2 percent to 8,789 points in September and the Nasdaq Biotechnology Index (NBI) slipped 0.1 percent, but was up 45.8 percent for the year.

The four Big Caps of Cochlear, CSL, Pro Medicus and Resmed, which are not included in the BDI-40, improved a collective 1.9 percent to \$160,295 million, but 22.4 percent below the \$206,509 million, a year ago.

CSL again led the Big Caps, recovering a further \$6,237 million or 7.6 percent to \$88,404 million, Cochlear climbed 4.2 percent to \$9,129 million, Pro Medicus was down 8.6 percent to \$17,125 million and Resmed fell 4.2 percent to \$45,637 million.

Micro-X was the September percentage best, from a low base, up \$23 million or 115.0 percent to \$43 million, followed by Curvebeam up 72.7 percent to \$19 million, Actinogen (34.8%), 4D Medical (24.6%), Resonance (21.4%), Starpharma (21.0%), Avita (16.2%), Alcidion (13.8%), Paradigm (pre-suspension; 11.7%) and Prescient (11.6%).

Imugene led the falls, down \$12 million or 34.3 percent to \$23 million, followed by Immutep (29.6%), Imricor (18.5%), Dimerix (17.9%), Cyclopharm (17.4%), Artrya (16.0%), Syntara (15.7%), Amplia (14.5%), Optiscan (13.0%), Proteomics (12.0%), Racura (11.2%), Mesoblast (10.6%) and Saluda (10.3%).

Outside the BDI-40, Echo IQ fell 57.5 percent from the billion-dollar club to \$445 million


Vitrafy was again at its highest end-of-month valuation at \$305 million, Cogstate climbed a further 10.1 percent to \$586 million, and PYC rose 15.5 percent to \$2,636 million, while Tissue Repair remained at \$5 million, down 72.2 percent for the year.

The 11 companies in Cannabis & Psychedelics Corner fell 3.78 percent for the month – up 45.8 percent for the 12 months to September 30, 2026 - led by Vitura down \$4 million or 23.5 percent to \$13 million, followed down by Argent (25.0%) and Avecho (18.0%); with Nexalis (Inhalerx) up 100 percent to \$4 million and Epsilon up 25 percent to \$10 million.


On the Nasdaq, Kazia lost 28.2 percent to \$158 million, Eyepoint (Psivida) fell 25.6 percent to \$395 million, and Queensland's Protagonist slipped 1.6 percent to \$13,124 million. Israel's Redhill Biopharma with Australian assets tumbled 50 percent to \$4 million, while Neuphoria (Bionomics) was unchanged at \$28 million.

Incannex was the only Australia biotechnology company on the Nasdaq to improve, up 5.4 percent to \$59 million.


BDI-40 v ASX200 Jun 30, 2006 to Sep 30, 2026- Adjusted



5-Year Big Caps \$m (COH, CSL, PME, RMD) To Sep 30, 2026



BDI-40 (\$m) v S&P ASX 200 – Jan 31, 2020 – Sep 30, 2026 (Pre-Covid to date)



[LTR PHARMA](#)

LTR says its 27-volunteer, phase II trial shows that Spontan nasal spray is faster in time-to-peak-blood-concentration than oral erectile dysfunction tablets ($p < 0.0001$).

Earlier this year, LTR said it had recruited its phase II, pharmacokinetic, clinical study of Spontan intra-nasal spray formulation of vardenafil, marketed as Levitra, for the treatment of erectile dysfunction (BD: Mar 5, 2026).

Today, the company said that 2.5mg and 5.0mg doses of Spontan reached peak blood concentration in a median time of 11 minutes and 10 minutes, respectively, compared to 60 minutes for the 20mg oral vardenafil tablet ($p < 0.0001$).

LTR said that the 5.0mg Spontan dose produced about a four-fold lower total exposure than the 20mg tablet, while doubling the Spontan dose from 2.5mg to 5mg “approximately doubled exposure”.

The company said “dose-normalized ... point estimates were broadly comparable across treatments ... [and] half-life was generally consistent with both routes, confirming that the principal difference between Spontan and the [varafenafil] tablet was in the absorption phase rather than elimination”.

LTR said “exposure to the major metabolite ... was substantially lower for Spontan than for the oral tablet, an expected result as intra-nasal delivery avoids first-pass metabolism”.

The company said five days of once-daily dosing showed no drug accumulation, with no clear pharmacokinetic differences observed between men aged 65 years and older, who made up 14 of the 27 participants, as well as younger adults.

LTR said both findings addressed requirements agreed with the US Food and Drug Administration at the pre-investigational new drug meeting.

The company said oral PDE5 inhibitors often required dose adjustment in older men.

LTR said Spontan was well tolerated and the safety analysis “did not identify any new or unexpected treatment-emergent adverse events”.

The company said treatment-related events were predominantly mild and self-resolving, with no serious adverse events, treatment discontinuations or study withdrawals.

LTR said “the most frequently reported treatment-related events included nasal congestion and headache, consistent with the known pharmacology of vardenafil and the intra-nasal route of administration”.

The company said that with the completion of the phase II trial it had met the pharmacokinetic dataset agreed with the FDA for a planned US Food and Drug Administration 505(b)(2) submission.

LTR said it would finalize its chemistry, manufacturing and controls package and begin “human factors validation, leachables and non-clinical toxicology”.

The company said that it expected to begin a phase III study by July 2027, with the dataset to support ongoing discussions with potential US licencing and commercial partners and engagement with the Australian Therapeutic Goods Administration and other regulators.

LTR executive chair Lee Rodne said that the company holds “a complete, independently reported dataset, designed to FDA specifications, confirming Spontan’s rapid-onset profile and favorable safety, with comparable pharmacokinetics in men aged 65 and over”.

“This is the evidence package US licencing partners and regulators need to see,” Mr Rodne said.

“Our focus now is progressing Spontan’s US development program, from preparations for the phase III study through to our planned 505(b)(2) submission, while converting our partnering discussions into commercial outcomes for shareholders,” Mr Rodne said.

LTR fell one cent or 2.1 percent to 47 cents.

MONASH UNIVERSITY

Monash University says with Bayside Health it is trialing combinations of antibiotics to treat persistent bacterial vaginosis (BV).

Monash University said the trials followed a study which found the condition was sexually transmissible and that treating male partners reduced BV recurrence in women by more than 60 percent.

The University said a second study showed “why some women continue to experience a repeat diagnosis of BV even when their male partners are treated concurrently, identifying two distinct pathways to repeat infection: re-infection and persistence of BV-bacteria”.

Monash University said the study, titled ‘Determinants of repeat bacterial vaginosis in concurrently treated couples: a post-hoc pooled cohort study’ was published in the Lancet Obstetrics, Gynaecology & Women’s Health at: <https://bit.ly/4dhvXPX>.

The University said the trials would assess treatments including longer duration and novel combinations of antibiotics designed to eradicate persistent BV-causing bacteria.

Monash University said the trials would use partner-treatment to mitigate re-infection and more intensive strategies that target persistence of BV-bacteria to develop more effective treatment approaches that could be tailored to an individual and achieve higher levels of cure for all women.

Monash University’s Dr Lenka Vodstrcil said “while partner treatment improves cure for most women in a monogamous relationship, there are some women who have persistent BV-bacteria that survive initial therapy before couples resume sex after treatment”.

“By identifying this early, we can intervene with more intensive female-focused treatments before the infection takes hold again,” Dr Vodstrcil said.

ADELAIDE UNIVERSITY

Adelaide University says “biodegradable films from engineered honeybee silk could form the basis of a new generation of ‘smart’ wound dressings”.

Adelaide University said that with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) it found recombinant honeybee silk could be bio-engineered in a laboratory to allow researchers to modify the protein sequence and potentially introduce features into the materials including infection-sensing signals or targeted drug release.

The University said the research, titled ‘Interaction of Biodegradable Recombinant Honeybee Silk Films with Acute Wound Healing Processes In Vivo’ was published in the Journal of Biomedical Materials Research Part B and the full article was available at:

<https://onlinelibrary.wiley.com/doi/10.1002/jbm.b.70138>.

Adelaide University said the study found the film was safe and well-tolerated during wound healing and “much of the silk film gradually broke down in the wound, rather than remaining as a permanent material”.

Adelaide University said the wound dressing could “potentially reduce the need to remove a dressing and disturb delicate new tissue as a wound heals”.

The University said the research was based on more than a decade of CSIRO research developing honeybee silk as a biomaterial platform, with previous studies showing the material was “strong, flexible, biodegradable and safe to use in biological applications”.

Adelaide University said that honeybee silk was different to spider or silkworm silk in that it was a naturally occurring protein material used by larvae to build protective structures in the hive and was made from proteins that were “strong, flexible and lightweight”.

Adelaide University said researchers were awarded an undisclosed Federal Government Medical Research Future Fund grant to develop and test several ‘smart’ dressings that might help prevent infections in chronic wounds.

SYNTARA (FORMERLY PHARMAXIS)

Syntara says eight of 20 patients in its SNT-6302 keloid scar trial discontinued treatment due to "mild, reversible local skin reactions after one month or more of treatment".

Last year, Syntara said the first of up-to 20 patients was dosed in a phase Ic trial of topical SNT6302, formerly PXS-6302, for keloid, or raised, scars led by the Fiona Wood Foundation and the University of Western Australia (BD: Jul 15, 2025).

Today, the company said six participants had completed the 12-week treatment period and remained in follow-up, with assessments planned to continue for nine months after treatment had concluded.

Syntara said preliminary findings in the six participants included an increase in blood-vessel area density at week 12, "consistent with findings in hypertrophic-scar participants". The company said no observable differences in patient and observer scar assessment scale scores or scar stiffness were identified at week 12.

Syntara said interpretation of the results was "limited by the exploratory nature of the study, the small number of participants completing treatment, and substantial heterogeneity in baseline scar size, anatomical location and scar age".

Syntara said the tolerability profile, with mainly erythema and pruritus reactions, was "consistent with observations in the earlier ... study of SNT-6302 and further supports [its] rationale for progressing its second-generation topical pan-LOX inhibitor, SNT-9465".

Syntara said it had expanded its 20-patient, phase Ib study of SNT-9465 for hypertrophic scars following sternotomy surgery to 30 patients.

Earlier this year, Syntara said 12 of 20 patients had begun treatment in its phase Ib study of topical pan-lysyl oxidase (pan-LOX) SNT-9465 (BD: Jul 1, 2026).

Today, the company said it expanded the double-blind, placebo-controlled study to 30 patients following "encouraging feedback from clinical sites and participant engagement".

Syntara said the expansion was "designed to provide a larger safety, tolerability and exploratory activity dataset and, with the study remaining blinded, is not based on treatment efficacy data".

The company said top-line study results were expected by April 2027.

Syntara fell 0.1 cents or 4.55 percent to 2.1 cents with 3.2 million shares traded.

CLINUVEL PHARMACEUTICALS

Clinuvel says three more vitiligo patients in its 'CUV105' study responded to Scenesse, or afamelanotide 16mg, with adjunct narrowband ultra-violet B phototherapy.

Last year, Clinuvel said it reached its 200-patient recruitment target in its phase III 'CUV105' trial of Scenesse for vitiligo; and earlier this year, said with results were expected "in December 2026" (BD: May 7, 2025; Jul 28, 2026).

Today, the company said the three participants, with Fitzpatrick skin types V and VI, responded to the treatment including follicular re-pigmentation observed within the lesions, with areas on the body and face either reaching confluence or homogeneity at the end of the treatment.

Clinuvel said treatment was well tolerated.

The company said "spontaneous re-pigmentation for up-to 24 weeks after completing the treatment, and without further intervention, was noted in all three participants, along with maintenance of re-pigmentation".

Clinuvel said the patient data was being presented to the European Academy of Dermatology and Venereology (EADV) conference held from September 30 to October 3, 2026 in Vienna, Austria.

Clinuvel fell 35 cents or 4.1 percent to \$8.25 with 143,877 shares traded.

AROVELLA THERAPEUTICS

Arovella says it has begun screening patients for its phase I trial of ALA-101 for CD19-positive non-Hodgkin lymphoma and leukaemia.

Last month, Arovella said it had manufactured the first clinical batch of ALA-101 for blood cancers and activated Melbourne's Alfred Hospital as the first trial site for its phase I study, with first patient dosing expected in September (BD: Sep 7, 2026).

Today, the company said dosing was expected "towards the end of October 2026".

Arovella said "since there is only a single dosing slot available at the beginning of the trial, patients are screened one at a time for ethical reasons".

The company did not disclose the number of patients expected to be enrolled.

Arovella acting chief executive officer Dr Nicole van der Weerden said the "level of interest from clinicians and patients in the ALA-101 study is exciting".

"There is no shortage of patients requiring treatment and we have everything in place to dose the first patient once eligibility is confirmed," Dr van der Weerden said.

Arovella fell 0.1 cents or 2.1 percent to 4.7 cents with 1.2 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says it has delayed its annual report due to negotiations with creditors and a recapitalization, with the ASX suspending the company under Listing Rule 17.5.

Earlier this year, Chimeric said it appointed Hawkesbury Partners to review options, had spent \$80 million on its clinical programs; and later, said it would close its phase I/II CHM-2101 gastro-intestinal cancer trial, due to safety, and had implemented \$4 million a year in major cost reductions, including staff (BD: Jul 1, Aug 19, 2026).

Today, the company said its 2025-'26 financial statements were "expected to include a material uncertainty in relation to [being a] going concern".

Chimeric said its preliminary final report on August 31, 2026 "reported a deficiency of net assets of approximately \$7.7 million".

The company said it continued to negotiate with its creditors, to settle its liabilities on an unconditional basis with the intention "to negotiate its valid and agreed liabilities to a level able to be satisfied by ... current financial resources, with binding deeds of settlement".

Chimeric said no agreement had been reached, and there was no certainty as to the outcome or timing of these negotiations.

The company said several parties had "expressed interest in providing funding to recapitalize the company" including a proposal to support a deeply discounted rights issue in which existing shareholders would be able to participate.

Chimeric said each expression of interest was conditional, including on a satisfactory outcome with creditors and no binding proposal had been received.

The company said it had reduced its activities to care and maintenance while the matters were progressed and it expected to remain suspended until the lodgment of its financial statements and the ASX was satisfied that it had met its requirements for reinstatement.

Chimeric last traded at 0.3 cents.

NYRADA INC

Nyrada says the US Patent and Trademark Office has granted a composition of matter patent covering Xolatryp, formerly NYR-BI03.

Nyrada said the patent, titled 'Compounds for Treatment of Excitotoxicity' would protect the chemical structure of its intellectual property until September 2044.

Nyrada was unchanged at 50 cents.

NEUROSCIENTIFIC BIOPHARMACEUTICALS

Neuroscientific says it has appointed Sydney's Southern Star Research as contract research organization (CRO) for its phase II trial of Stemsmart for Crohn's disease. Last year, Neuroscientific said it completed its acquisition of Perth's Isopogen WA and its Stemsmart mesenchymal stem cells for scrip; and later, said it had dosed four Crohn's disease patients with Stemsmart under an Australian Therapeutic Goods Administration special access program (BD: Jun 27, Nov 11, 2025).

Earlier this year, the company said it would hold a US Food and Drug Administration pre-investigational new drug meeting for a planned phase II trial of Stemsmart in Crohn's disease (BD: Aug 13, 2026).

Today, Neuroscientific said Southern Star would manage the clinical sites, engage with clinicians and coordinate Stemsmart treatment logistics, with the trial expected to begin by the end of 2026.

Neuroscientific was up 0.1 cents or 1.6 percent to 6.2 cents.

ADALTA

Adalta says it has Shanghai Municipal Administration for Market Regulation approval to open a representative office in Shanghai, China.

Adalta said the representative office provided a physical presence in the country that supplies the innovation its 'East to West' strategy was built to bring to Western patients and partners.

Earlier this year, the company said through its Adcella 'East to West' strategy it would invest about \$US22-31 million (\$A32-45 million) to develop Shanghai Cell Therapy's BZDS1901, now EW-001, outside China (BD: Jan 18, 2026).

Today, Adalta said the representative office was "an established legal form through which a foreign company sets up an official but cost-effective presence in China".

The company said the office allowed it "to engage local staff and contractors who represent and promote the company in China, working in the same country, the same language and the same time zone as its partners".

Adalta managing-director Dr Tim Oldham said China was "where the cellular immunotherapies we want to licence are being invented and tested, and relationships in this industry are not built over video calls alone".

"This approval gives Adalta the ability, for the first time, to have its own people on the ground in China, managing our collaboration with [Shanghai Cell Therapy], sitting across the table from the next generation of Chinese innovators, and building the partnerships that make our 'East to West' model repeatable," Dr Oldham said.

Adalta was up 0.05 cents or 14.3 percent to 0.4 cents with 6.6 million shares traded.

CORRECTION: PAINCHEK

Last night's edition incorrectly said chair Lil Bianchi's 415,369 long-term incentive performance rights worth \$40,000 were "in addition to Ms Bianchi's \$120,000 yearly pay". In fact, the notice of meeting made clear the rights comprised one third of her yearly fee. We apologize unreservedly to Painchek and Ms Bianchi for the error and have removed the article from the on-line edition.

The error was made by the Tuesday sub-editor, who to be fair, had a lot of articles to report; and who has been severely admonished and not physically hurt, at this time.

Painchek fell 0.1 cents or one percent to 9.5 cents.

OPTISCAN IMAGING

Optiscan says it has filed a US Food and Drug Administration 510(k) submission with the US Food and Drug Administration for its Inform pathology microscope system.

Last year, Optiscan said Inform was a medical imaging device, for laboratory medicine, pathology practices, point-of-care and digital pathology (BD: Feb 19, 2025).

Today, the company said the filing was “a major deliverable in Inform’s development strategy, being a necessary prerequisite for regulatory clearance of the device by the FDA, and its subsequent commercialization in the US”.

Optiscan said the Inform device enabled “real-time, slide-free digital microscopic imaging to be reviewed directly from freshly excised tissue at the point-of-contact or from tissue fixed in preservatives commonly used in pathology [laboratories]”.

The company said Inform would enter the FDA’s formal 510(k) review process, including an initial acceptance assessment followed by substantive review of the device’s technical, performance and supporting evidence.

Optiscan said a successful 510(k) determination “should provide FDA clearance for Inform to be commercially distributed in the US for its cleared indications”.

The company did not disclose the indications.

Optiscan managing-director Prof Camile Farah said the submission was “a key deliverable in our pathology device’s development strategy”.

“The device is not just digitising an existing pathology process ... [Inform] has real potential to change where and when microscopic information becomes available for clinical use,” Prof Farah said.

“Submitting our FDA submission brings us closer to introducing a fundamentally different workflow into the U.S., one of the world’s largest pathology markets,” Prof Farah said.

“While Inform’s regulatory approval process is progressed, Optiscan and its collaborators will continue to generate valuable clinical evidence that will be critical in demonstrating where Inform’s value ... can be realized,” Prof Farah said.

Optiscan was up 2.5 cents or 18.5 percent to 16 cents.

ADHERIS HEALTH (FORMERLY MEDADVISOR)

Adheris says members of its board and management have acquired about 27,000,000 shares on market at one cent a share, representing 4.2 percent of the shares on issue.

Adheris said a long-term supportive shareholder had additionally acquired a further 27,000,000 shares, representing 4.2 percent of the current shares outstanding.

According to four Appendix 3Ys, chair Kate Hill acquired 1,000,000 shares, with managing-director John Ciccio and directors Lucas Merrow and John Murray acquiring 2,906,211 shares, each, at one cent a share.

Ms Hill said the board and management were “pleased to be increasing their investment in the company”.

“We are encouraged by the momentum returning to the business, which reflects the strength of our people, the quality of our customer relationships and the progress being made across the organization,” Ms Hill said.

“As we continue to execute on our strategic initiatives, we remain focused on rebuilding shareholder value and trust and are optimistic about the opportunities ahead,” Ms Hill said.

Last year, the then Medadvisor said it completed the \$35 million sale of its Australia and New Zealand business operations to Jonas Software (BD: Jul 7, 2025)

Adheris was unchanged at 1.3 cents.

ARGENT BIOPHARMA (MGC PHARMACEUTICALS)

Argent says it has taken two \$US250,000 (\$A360,000) loans from WVP Emerging Manager Onshore Fund LLC and C/M Capital Master Fund LP.

Argent said the non-revolving cash advance loans were repayable within nine months from draw-down at \$US287,500 each, with no ongoing interest charges.

The company said the loans were unsecured and had a default interest rate of 18 percent a year on overdue amounts and were repayable within 15 days if it completed a capital raise of at least \$5.0 million from third parties.

Argent said the loans would fund working capital requirements, covering corporate costs and research and development activities.

The company said each lender was a counterparty to a convertible securities agreement and not related parties or substantial shareholders.

Last year, Argent said it had an up-to \$11 million finance agreement with the Cayman Islands-based C/M Capital and New York's WVP Emerging Manager Onshore Fund to fund its acquisition of Auscann and had drawn \$3 million with the remaining funds available within 18 months; convertible at the lower of 10 cents or 90 percent of the lowest 15-day volume weighted average price to the conversion notice, but no less than four cents (BD: Nov 17, 2025).

Argent was unchanged at 3.2 cents.

ARTRYA

David Paradise says with Paradise Investment Management he has increased his holding in Artrya from 11,387,931 shares (6.9679%) to 13,109,470 shares (8.0213%).

Sydney's Mr Paradise said that between September 21 and 28, 2026 he bought a total 1,721,539 shares in six transactions for \$5,267,680, or \$3.06 cents a share.

Artrya fell 13 cents or 3.65 percent to \$3.43 with 1.1 million shares traded.

MICROBA LIFE SCIENCES

Mercer Investments says it has increased its substantial shareholding in Microba from to 53,123,105 shares (7.586%) to 62,564,981 shares (8.725%).

Melbourne's Mercer said that between July 10 and September 25, 2026 it bought shares at prices ranging from 3.94 cents to 5.18 cents a share.

Microba was unchanged at 4.9 cents.

STARPHARMA HOLDINGS

Starpharma says director Dr Russell Bassar has been appointed as chair, replacing Rob Thomas who will retire at the annual general meeting in November.

Starpharma said it thanked Mr Thomas for "12 years of distinguished service as chair".

The company said Dr Bassar would assume the role of chair following the close of the annual general meeting, with director David McIntyre appointed deputy chair.

Starpharma said it had requested Mr Thomas continue as a non-executive director, subject to shareholder approval at the meeting, to support an orderly transition.

The company said the changes reflected its focus on targeted oncology therapies and broader international engagement.

In 2020, Starpharma said it appointed Mr McIntyre as a director; and later in 2023, said it appointed Dr Bassar as an independent director (BD: Feb 12, 2020; Jan 31, 2023).

Starpharma fell 7.5 cents or 8.6 percent to 79.5 cents with 5.4 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says Phillip Hains is its interim chair, Dr Rebecca McQualter has been promoted to managing-director, with directors Brad Glover and Lesley Russell retiring.

Chimeric said that it had “significantly reduced its US operations, including in relation to the close out of the phase I clinical study and a reduction in US-based employees” (see above) and had downsized the board with immediate effect.

The company said that following the changes its board comprised of Mr Hains, Dr McQualter and Prof Miles Prince.

NEXSEN

Nexsen says it has appointed Prof Shekhar Kumta as executive director on \$275,000 a year, with executive chair Reece O’Connell to transition to non-executive chair.

Last year, Nexsen said it appointed Prof Kumta as a non-executive director (BD: Dec 3, 2025).

Today, the company said Prof Kumta’s executive responsibility was to lead its “growing portfolio of point-of-care diagnostics” including overseeing the progression of development programs, leading its expanding Hong Kong-based technical team, and driving programs from development toward market rollout.

Nexsen said the transition reflected its increased focus on technical execution, product development and market rollout, with Mr O’Connell continuing to support the company in capital markets, governance and commercial strategy.

The company said Prof Kumta would be paid \$275,000 a year plus superannuation and receive 10,000,000 options exercisable at 40 cents each by September 11, 2029, subject to shareholder approval.

Nexsen said Mr O’Connell would be paid \$100,000 a year excluding superannuation following his transition to non-executive chair.

Nexsen fell one cent or eight percent to 11.5 cents.

BTC HEALTH

BTC says it has appointed Dr Ian Kadish as a director, effective from October 1, 2026.

BTC said Dr Kadish had been a consultant at McKinsey & Co and CSC Healthcare, executive director of Netcare, managing-director of Healthcare Australia and Pulse Health Group, chief executive officer of Laverty Pathology, chief operating officer of Greencross and chief executive officer of Integral Diagnostics.

The company said Dr Kadish was currently a Teaminvest Private Group director and aN Australian Diagnostic Imaging Association director.

BTC said Dr Kadish held a Master of Business Administration from Philadelphia, Pennsylvania’s Wharton School of the University of Pennsylvania.

BTC was untraded at 5.7 cents.

NEURIZON THERAPEUTICS

Neurizon says Dr Chris Bremer has begun as chief executive officer, with Sergio Duchini to transition from interim executive chair to non-executive chair.

Last month, Neurizon said it appointed Dr Bremer as its chief executive officer on \$450,000 a year, plus incentives, effective from October 1, 2026 (BD: Sep 7, 2026).

Neurizon fell 0.3 cents or 3.85 percent to 7.5 cents.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT SEP 30, 2026

Company \$Am	Sep 30, 2025	Aug 31, 2026	Sep 30, 2026
Cochlear	18,263	8,758	9,129
CSL	96,157	82,167	88,404
Pro Medicus	32,220	18,741	17,125
Resmed	59,869	47,659	45,637
BDI-20			
4D Medical	996	2,052	2,557
Aroa	224	192	182
Avita	247	431	501
Clarity	1,324	851	783
Clinuvel	591	404	434
Compumedics	53	51	48
Cyclopharm	88	69	57
Dimerix	312	168	138
EBR Systems	510	232	237
Immutep	389	71	50
Imricor	451	697	568
Medical Developments	81	52	49
Mesoblast	3,034	3,065	2,740
Nanosonics	1,283	825	880
Neuren	2,493	2,503	2,580
Nova Eye	47	40	38
Orthocell	349	208	208
Polynovo	984	694	639
Syntara	47	51	43
Telix	4,931	5,219	5,343
Second 20			
Actinogen	105	161	217
Alcidion	133	130	148
Amplia	77	69	59
Artrya	347	693	582
Atomo	24	16	16
Botanix	314	55	50
Curvebeam	44	11	19
Emvision	176	159	148
Impedimed	75	18	18
Imugene	90	35	23
Lumos	114	99	97
Micro-X	54	20	43
Optiscan	89	162	141
Paradigm	138	137	153
Prescient	44	69	77
Proteomics	57	25	22
Racura Oncology	545	418	371
Resonance	18	28	34
Saluda	89	117	105
Starpharma	107	343	415

* Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Amplia, Clarity, Cochlear, EBR, Nanosonics, Neuren, Patrys, Percheron, Polynovo and Telix, as well as unlisted and non-biotech stocks.

Through Australian Ethical Superannuation he has an indirect interest in other companies:

<https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/>. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 500, Flemington, Victoria, Australia, 3031
email: editor@biotechdaily.com.au; www.biotechdaily.com.au